Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.
Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.
What's Your Reaction?
